These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37470295)

  • 21. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.
    Patel MK; Kaye AD; Urman RD
    J Anaesthesiol Clin Pharmacol; 2018; 34(1):111-116. PubMed ID: 29643634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
    Jonsson EN; Xie R; Marshall SF; Arends RH
    Br J Clin Pharmacol; 2016 Apr; 81(4):688-99. PubMed ID: 26613544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
    Schnitzer TJ; Marks JA
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
    Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human β-nerve growth factor.
    Neubert H; Muirhead D; Kabir M; Grace C; Cleton A; Arends R
    Anal Chem; 2013 Feb; 85(3):1719-26. PubMed ID: 23249404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.
    Cattaneo A
    Curr Opin Mol Ther; 2010 Feb; 12(1):94-106. PubMed ID: 20140821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor.
    Liu S; Shen Y; Chen P; Guo C; Zhang G; Jiang X; He J; Yang J
    Protein Expr Purif; 2022 Jan; 189():105966. PubMed ID: 34627999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pro region engineering of nerve growth factor by deep mutational scanning enables a yeast platform for conformational epitope mapping of anti-NGF monoclonal antibodies.
    Medina-Cucurella AV; Zhu Y; Bowen SJ; Bergeron LM; Whitehead TA
    Biotechnol Bioeng; 2018 Aug; 115(8):1925-1937. PubMed ID: 29663315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
    Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
    Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic.
    Hefti F
    Pharmacol Res; 2020 Apr; 154():104240. PubMed ID: 31026504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.
    Hoffman EM; Zhang Z; Anderson MB; Schechter R; Miller KE
    Neuroscience; 2011 Oct; 193():452-65. PubMed ID: 21802499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
    Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tanezumab for the treatment of pain from osteoarthritis of the knee.
    Lane NE; Schnitzer TJ; Birbara CA; Mokhtarani M; Shelton DL; Smith MD; Brown MT
    N Engl J Med; 2010 Oct; 363(16):1521-31. PubMed ID: 20942668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tanezumab: a selective humanized mAb for chronic lower back pain.
    Webb MP; Helander EM; Menard BL; Urman RD; Kaye AD
    Ther Clin Risk Manag; 2018; 14():361-367. PubMed ID: 29503555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
    Bannwarth B; Kostine M
    Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analgesic effects of nerve growth factor-directed monoclonal antibody on diabetic neuralgia in an animal model.
    Dong X; Li H; Pei M; Tan J; Chen G; Li S; Xie Z; Wang Q; Wang G; Chen YL; Wang C
    FEBS Open Bio; 2022 Jul; 12(7):1325-1335. PubMed ID: 35417079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee.
    Conaghan PG; Dworkin RH; Schnitzer TJ; Berenbaum F; Bushmakin AG; Cappelleri JC; Viktrup L; Abraham L
    J Rheumatol; 2022 Jun; 49(6):615-621. PubMed ID: 35232805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
    Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
    Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.